Rochester, NY (PRWEB) December 22, 2013 -- Studies show that head and neck cancer patients face “a dramatically high lifetime risk of developing a second primary cancer (SPC),” according to the journal of Oral Oncology in a study published in January 2013 (2). These second cancers include “the lung, esophagus and head and neck sites (2),” with a “cumulative SPM (second primary malignancy) incidence of 36% at 20 years among patients with HNSCC (Head and Neck Squamous Cell Carcinoma)”, according to a study published in May 2011 in the journal Cancer Causes & Control (3). In particular, the risk of developing lung cancer is particularly high. As study authors wrote, “…the excess risk of lung SPC remains high… (2).”
This is important information, especially for men. “Over the past decade, a rise in incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell cancers (HNSCC) in white men younger than 50 years of age has been recorded (2).”
In addition, “Citing the national population-based database maintained by the Danish Head and Neck Cancer Group (DAHANCA), Dr. Pernille Lassen reported a striking 12-fold increase in oropharyngeal cancer between 1977 and 2012, with HPV-positive disease increasing from 37% to 74%,” according to an article published on October 17, 2013 on the Medscape website (4).
The article quoted Dr. Lassen saying that men who smoke and have HPV cancers are harder to treat, and have a worse prognosis. “‘…an increasing number of patients are being identified with tumors with carcinogenic features from both HPV and tobacco use. ‘In terms of clinical outcome, these patients fare significantly worse than those with pure HPV-induced tumors and somewhat better than those with HPV-negative (tobacco-induced) carcinomas,’ Dr. Lassen noted. ‘These tumors with dual/mixed etiology represent a challenge both in terms of molecular biology and treatment selection,’ she acknowledged (4).” Dr. Lassen is a researcher from Aarhus University Hospital in Aarhus, Denmark.
“It’s obvious that as HPV caused head and neck cancers rise, so will the risk of other cancers, especially lung cancer. We recommend that men take Gene-Eden-VIR, which was clinically proven to reduce symptoms associated with HPV infection.” – Mike Evans, polyDNA.
A study published on August 12, 2013 in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs, showed that Gene-Eden-VIR reduced HPV symptoms. Study authors wrote that, “Individuals infected with the HPV…reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR (5).” The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms (5).”
To learn more about Gene-Eden-VIR, and HPV visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.
(1) Survivorship--competing mortalities, morbidities, and second malignancies. Published in August 2013.
(2) Trends over three decades of the risk of second primary cancer among patients with head and neck cancer
(3) Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. Published in May 2011.
(4) HPV Head and Neck Cancer: The New Threat
(5) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.
In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.
polyDNA developed Gene-Eden-VIR, an antiviral natural remedy that helps the immune system kill latent viruses.
Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]